Comparing nebulized colistin with nebulized Amikacin- Fosfomycin as an adjunctive treatment of ventilator associated pneumonia due to multi drug resistant acinetobacter

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171230038142N13

Enrollment

Registered

2020-03-02

Start date

2019-08-23

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator associated pneumonia due to multi drug resistant acinetobacter. Ventilator associated pneumonia

Interventions

Intervention 1: Intervention group: The inhaled Amikacin + phosphomycin treatment group (treated with intravenous meropenem and clistine) included 30 patients with ventilator-associated pneumonia, who

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patient hospitalization in ICU Age between 20 and 85 Diagnosis of ventilator pneumonia for the patient Diagnosis of cholesterol-sensitive Acinetobacter baumannii Patient satisfaction

Exclusion criteria

Exclusion criteria: Diagnosis Another concomitant disease Start treatment of acinetobacter

Design outcomes

Primary

Measure	Time frame
Mortality rates. Timepoint: After completing the study. Method of measurement: Counting the number of patients.;Duration of response to treatment. Timepoint: After completing the study. Method of measurement: Counting the number of days admitted and the number of patients saved.;CPIS index. Timepoint: Before and after treatment. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtusa Hakami Fafd

Esfahan University of Medical Sciences

a.hakamifard@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026